XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Consolidation, Policy [Policy Text Block]
Principles of Consolidation
 
The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics, B.V., which was organized in the Netherlands in
March 2015.
Heron Therapeutics, B.V. has
no
operations and
no
material assets or liabilities, and there have been
no
significant transactions related to Heron Therapeutics, B.V. since its inception.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our significant accounting policies that involve significant judgment and estimates include revenue recognition, inventory, accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.
Cash, Cash Equivalents, and Short-Term Investments [Policy Text Block]
Ca
sh, Cash Equivalents and Short-t
erm Investments
 
Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of
three
months or less.
 
 
Short-term investments consist of securities with contractual maturities of greater than
three
months to
one
year. We have classified our short-term investments as available-for-sale securities in the accompanying unaudited condensed consolidated financial statements. Available-for-sale securities are stated at fair market value, with net changes in unrealized gains and losses reported in other comprehensive loss and realized gains and losses included in other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest and dividends on securities classified as available-for-sale are included in interest income.
 
Our bank and investment accounts have been placed under control agreements in accordance with our Senior Secured Convertible Notes (“Convertible Notes”) and our Subordinated Secured Promissory Note (“Promissory Note”) (see Note
10
).
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentration of Credit Risk
 
Cash, cash equivalents and short-term investments are financial instruments that potentially subject us to concentrations of credit risk. We deposit our cash in financial institutions. At times, such deposits
may
be in excess of insured limits. We
may
also invest our excess cash in money market funds, U.S. government and agencies, corporate debt securities and commercial paper. We have established guidelines relative to our diversification of our cash investments and their maturities in an effort to maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.
 
Our products are distributed in the U.S. through a limited number of specialty distributors and full line wholesalers (collectively, “Customers”) that resell our products to healthcare providers and hospitals, the end users.
 
The following table includes the percentage of net product sales and accounts receivable balances for our major Customers, which are Customers comprising
10%
or more of our net product sales:
 
   
Net Product Sales
    
Accounts
Receivable
  
   
Three Months Ended
June 30, 2018
    
Six Months Ended
June 30, 2018
    
As of
June 30, 2018
  
                         
Customer A
    
47.0
 %    
55.8
 %    
58.4
 %
Customer B
    
31.3
 %    
21.3
 %    
22.7
 %
Customer C
    
21.2
 %    
22.6
 %    
18.7
 %
Total
    
99.5
 %    
99.7
 %    
99.8
 %
Receivables, Policy [Policy Text Block]
Accounts Receivable, Net
 
Accounts receivable are recorded at the invoice amount net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects accounts receivable balances that are believed to be uncollectible. In estimating the allowance for doubtful accounts, we consider: (
1
) our historical experience with collections and write-offs; (
2
) the credit quality of our Customers and any recent or anticipated changes thereto; and (
3
) the outstanding balances and past due amounts from our Customers.
 
We offered extended payment terms to our Customers in connection with our product launches of SUSTOL and CINVANTI in
October 2016
and
January 2018,
respectively, in anticipation of the timing in reimbursement by government and commercial payers. Effective
January 2018,
we shortened payment terms to certain of our SUSTOL Customers. As of
June 30, 2018,
extended payment terms given to our Customers were evaluated in accordance with GAAP and did
not
impact the collectability of accounts receivables.
 
As of
June 30, 2018,
we determined that an allowance for doubtful accounts was
not
required. For the
three
and
six
months ended
June 30, 2018,
we did
not
write off any accounts receivable balances.
Inventory, Policy [Policy Text Block]
Inventory
 
Inventory is stated at the lower of cost or estimated net realizable value on a
first
-in,
first
-out, or FIFO, basis. We periodically analyze our inventory levels and write down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory quantities that are in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory
may
be required, which would be recorded as a cost of product sales.
Revenue Recognition, Policy [Policy Text Block]
Revenue Recognition
 
In
May 2014,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.
2014
-
09,
Revenue from Contracts with Customers
(“Topic
606”
). Topic
606
is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Topic
606
is effective for fiscal years beginning after
December 15, 2017,
including interim periods within those fiscal years. Accordingly, in the
first
quarter of
2018,
we adopted Topic
606
using the modified retrospective approach. Under this approach, incremental disclosures are provided to present each financial statement line item for
2018
under the prior standard. As a result of the adoption of Topic
606,
we recorded a cumulative adjustment to retained earnings of
$1.6
million on
January 1, 2018.
This adjustment reflects the acceleration of
$2.9
 million in gross product sales less
$1.1
 million in product sales allowances and
$0.2
million in cost of product sales (see Note
7
).
Comprehensive Income, Policy [Policy Text Block]
Comprehensive Loss
 
Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net changes in unrealized gains and losses on available-for-sale securities are included in other comprehensive loss and represent the difference between our net loss and comprehensive loss for all periods presented.
Earnings Per Share, Policy [Policy Text Block]
Net L
oss
per Share
 
Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and shares of common stock underlying Convertible Notes are considered to be common stock equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive.
 
Because we have incurred a net loss for all periods presented in the unaudited condensed consolidated statements of operations and comprehensive loss, stock options, warrants and shares of common stock underlying Convertible Notes are
not
included in the computation of net loss per share because their effect would be anti-dilutive. The following table includes the number of stock options, warrants and shares of common stock underlying Convertible Notes
not
included in the computation as of the dates shown below (in thousands):
 
 
   
 
As of
June 30
,
  
   
2018
    
2017
  
                 
Stock options outstanding
    
12,514
      
11,966
  
Warrants outstanding
    
640
      
625
  
Shares of common stock underlying Convertible Notes outstanding
    
8,224
      
7,749
  
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements
 
Recently Adopted
 
In
May 2017,
FASB issued ASU
No.
2017
-
09,
Compensation
– Stock Compensation
: Scope of Modification Accounting
(“ASU
2017
-
09”
).
The amendments in ASU
2017
-
09
provide guidance about which changes to the terms or conditions of a stock-based payment award require an entity to apply modification accounting in Topic
718.
In the
first
quarter of
2018,
we adopted the provisions of ASU
2017
-
09,
which did
not
have a material impact on our results of operations or financial condition.
 
Not
Yet Adopted
 
In
February 2016,
FASB issued ASU
No.
2016
-
02,
Leases
(“ASU
2016
-
02”
). ASU
2016
-
02
requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than
12
months. In addition, ASU
2016
-
02
requires both lessees and lessors to disclose certain key information about lease transactions. ASU
2016
-
02
is effective for fiscal years beginning after
December 15, 2018,
including interim periods within those fiscal years. We plan to adopt the provisions of ASU
2016
-
02
in the
first
quarter of
2019,
and we are currently evaluating the impact on our results of operations and financial condition.